• Home
  • Search Results
  • Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy.

Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy.

ACS nano (2014-11-18)
Liwen Zhang, Shi Gao, Fan Zhang, Kai Yang, Qingjie Ma, Lei Zhu

Photothermal therapy (PTT) is an emerging treatment modality that is under intensive preclinical investigations for the treatment of various medical conditions, including cancer. However, the lack of targeting function of PTT agents hampers its clinical application. An effective and nontoxic delivery vehicle that can carry PTT agents into tumor areas is still needed urgently. In this study, we developed a multifunctional nanocomposite by loading copper sulfide (CuS) into Cy5.5-conjugated hyaluronic acid nanoparticles (HANP), obtaining an activatable Cy5.5-HANP/CuS (HANPC) nanocomposite. In this system, Cy5.5 fluorescent signal is quenched by CuS inside the particle until the whole nanocomposite is degraded by hyaluronidase present in tumor, giving strong fluorescence signals delineating the tumor. Importantly, CuS with strong NIR absorbance appears to be an excellent contrast agent for photoacoustic (PA) imaging and an effective PTT agent. After intravenous administration of HANPC into SCC7 tumor-bearing mice, high fluorescence and PA signals were observed in the tumor area over time, which peaked at the 6 h time point (tumor-to-normal tissue ratio of 3.25±0.25 for optical imaging and 3.8±0.42 for PA imaging). The tumors were then irradiated with a laser, and a good tumor inhibition rate (89.74% on day 5) was observed. Our studies further encourage application of this HA-based multifunctional nanocomposite for image-guided PTT in biomedical applications, especially in cancer theranostics.

Product Number
Product Description

Propidium iodide, ≥94.0% (HPLC)
Tetrabutylammonium hydroxide solution, ~40% in water, suitable for ion chromatography
Tetrabutylammonium hydroxide solution, 40 wt. % in H2O
Tetrabutylammonium hydroxide solution, 1.0 M in methanol
Propidium iodide solution, solution (1.0 mg/ml in water)
2-Thiobarbituric acid, ≥98%
Calcein-AM, BioReagent, suitable for fluorescence, ≥95.0% (HPLC)
Propidium iodide, ≥94% (HPLC)
Calcein AM solution, 4 mM in DMSO, ≥90% (HPLC), solution
Tetrabutylammonium hydroxide solution, technical, ~40% in H2O (~1.5 M)
Calcein-AM, Small Package (20 X 50 μg ), ≥95.0% (HPLC)
Tetrabutylammonium hydroxide solution, 54.0-56.0% in H2O

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.